In recent years, specific inhibitors of BRAF/MEK/ERK pathway alone or in combination have been used in patients with advanced melanoma and, although resistance to a combined therapy with BRAF inhibitor and MEK inhibitor resulted in a prolonged patients’ survival compared to treatment with the single agents, resistance remains a significant problem [20]. Here, MAP2K7 is linked to melanoma.